Invention Grant
- Patent Title: Soluble endoglin and uses thereof
- Patent Title (中): 可溶性内皮糖蛋白及其用途
-
Application No.: US13521849Application Date: 2011-01-11
-
Publication No.: US08795663B2Publication Date: 2014-08-05
- Inventor: Mourad Toporsian
- Applicant: Mourad Toporsian
- Applicant Address: US MA Boston
- Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee Address: US MA Boston
- Agency: Clark & Elbing LLP
- Agent Kristina Bieker-Brady
- International Application: PCT/US2011/020841 WO 20110111
- International Announcement: WO2011/088047 WO 20110721
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/18 ; A61K39/395

Abstract:
The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits containing these materials. The invention also provides methods for treating or decreasing the likelihood of developing a soluble endoglin-mediated disorder in a subject requiring the administration of an agent capable of reducing the expression or biological activity of a soluble endoglin polypeptide and methods for treating or decreasing the likelihood of developing a soluble endoglin-preventive disorder in a subject requiring the administration of a soluble endoglin polypeptide or a nucleic acid encoding the soluble endoglin polypeptide. The invention further provides methods for the diagnosis of a soluble endoglin-mediated disorder or a soluble endoglin-preventive disorder and methods for identifying a compound to treat a soluble endoglin-mediated or a soluble endoglin-preventive disorder.
Public/Granted literature
- US20130136745A1 SOLUBLE ENDOGLIN AND USES THEREOF Public/Granted day:2013-05-30
Information query